Deucravacitinib

Generic Name: Deucravacitinib

Brand Names: Sotyktu

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₃

CAS Number: 1609392-27-9

Unique Ingredient Identifier: N0A21N6RAU

Background: Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved...

Indication: Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.

Associated Conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2022-07-28

Last Posted Date: 2024-11-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 152

Registration Number: NCT05478499

Locations: 🇺🇸
Local Institution - 0001, Hot Springs, Arkansas, United States
🇺🇸
Local Institution - 0007, Indianapolis, Indiana, United States
🇺🇸
Local Institution - 0041, Louisville, Kentucky, United States

and more 26 locations

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

Early Phase 1

Recruiting

Conditions: Nail Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2021-11-17

Last Posted Date: 2024-03-15

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT05124080

Locations: 🇺🇸
University of Alabama at Birmingham - Department of Dermatology, Birmingham, Alabama, United States

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Deucravacitinib
Drug: Famotidine

First Posted Date: 2021-07-02

Last Posted Date: 2022-03-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT04949269

Locations: 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Phase 3

Active, not recruiting

Conditions: Psoriatic Arthritis

Interventions: Other: Placebo
Drug: Deucravacitinib

First Posted Date: 2021-06-01

Last Posted Date: 2024-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 650

Registration Number: NCT04908202

Locations: 🇨🇳
Local Institution - 0122, Tainan, Taiwan
🇨🇳
Local Institution - 0120, Taipei City, Taiwan
🇨🇳
Local Institution - 0124, Taoyuan, Taiwan

and more 178 locations

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Phase 3

Active, not recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: Deucravacitinib
Drug: Apremilast
Other: Placebo

First Posted Date: 2021-06-01

Last Posted Date: 2024-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 729

Registration Number: NCT04908189

Locations: 🇦🇷
Local Institution - 0200, Buenos Aires, Argentina
🇦🇺
Local Institution - 0018, Paramatta, New South Wales, Australia
🇦🇺
Local Institution - 0002, Camberwell, Victoria, Australia

and more 144 locations

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Phase 2

Completed

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: Deucravacitinib

First Posted Date: 2021-05-07

Last Posted Date: 2023-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 67

Registration Number: NCT04877990

Locations: 🇺🇸
Local Institution - 0036, Shreveport, Louisiana, United States
🇯🇵
Local Institution - 0026, Bunkyo-ku, Tokyo, Japan
🇺🇸
Local Institution - 0002, Wyoming, Michigan, United States

and more 38 locations

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Phase 2

Active, not recruiting

Conditions: Lupus Erythematosus, Discoid
Lupus Erythematosus, Subacute Cutaneous

Interventions: Drug: Deucravacitinib
Drug: Placebo

First Posted Date: 2021-04-23

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 75

Registration Number: NCT04857034

Locations: 🇲🇽
Local Institution - 0071, Mexico City, Mexico
🇨🇳
Local Institution - 0022, Taipei, Taiwan
🇺🇸
Local Institution - 0059, Saint Louis, Missouri, United States

and more 38 locations

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo matching deucravacitinib

First Posted Date: 2021-02-26

Last Posted Date: 2024-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 153

Registration Number: NCT04772079

Locations: 🇧🇷
Local Institution - 0083, Rio de Janeiro, Brazil
🇧🇷
Local Institution - 0067, São Paulo, Brazil
🇨🇦
Dermatology Research Institute, Calgary, Alberta, Canada

and more 58 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy